Bronchiolitis Obliterans Organizing Pneumonia (BOOP)

Bronchiolitis Obliterans Organizing Pneumonia (BOOP)—most often called Organizing Pneumonia (OP), and Cryptogenic Organizing Pneumonia (COP) is a healing response of the lung after injury. Instead of the air sacs (alveoli) clearing normally, tiny plugs of healing tissue (granulation tissue) form inside the air spaces and small airways. These plugs are often called Masson bodies. They block airflow in small areas and create patchy spots of inflammation and consolidation on scans. The lung’s basic structure stays intact; the problem is the filling and plugging rather than scarring that stiffens the entire lung. When doctors can’t find a trigger, it’s called cryptogenic organizing pneumonia (COP). When a trigger is found (such as a drug, radiation, infection, or an autoimmune disease), it’s called secondary organizing pneumonia. NCBI+1

Organizing pneumonia is a lung condition where tiny plugs of healing tissue (called granulation tissue) grow inside the small airways and air sacs. These plugs block airflow and oxygen exchange, causing cough and breathlessness. OP is a healing response the lung uses after injury: infection, medicines, radiation, autoimmune diseases, or unknown causes (then it’s called COP). On scans, OP often looks like patchy, migrating areas of lung “whiteness” (consolidation). Most people improve well with corticosteroids, though some relapse and a few develop scarring. Diagnosis is based on symptoms, CT patterns, and sometimes lung biopsy to see the typical “Masson bodies” (organized plugs) under the microscope. PubMed Central+2publications.ersnet.org+2

Other names

• Cryptogenic Organizing Pneumonia (COP) – idiopathic form (no identified cause).

• Bronchiolitis Obliterans Organizing Pneumonia (BOOP) – older name you’ll still see; it refers to plugs that can obstruct small airways.

• Organizing Pneumonia (OP) – umbrella term that includes both cryptogenic and secondary cases.
  Professional societies now prefer OP/COP and reserve BOOP mainly for historical use. publications.ersnet.org+1

Types

1. Cryptogenic OP (COP): OP with no clear cause after careful evaluation. Often subacute (weeks) with cough, breathlessness, low-grade fever, and malaise; usually responds to corticosteroids but may relapse. MSD Manuals+1

2. Secondary OP: Same pathology, but a trigger is identified—drug toxicity, radiation to the chest, infection, autoimmune/connective-tissue disease, environmental exposure, post-transplant, or post-COVID inflammatory injury. Removing the trigger and treating inflammation are key. www.elsevier.com

3. Focal (solitary) OP: A single nodule or mass-like opacity; can mimic cancer on imaging or PET, so biopsy is often needed. publications.ersnet.org

4. Diffuse/multifocal OP: Multiple patchy consolidations, often peripheral and migratory; classic for COP. publications.ersnet.org

5. Fulminant OP: Rare, rapidly progressive respiratory failure resembling ARDS; urgent recognition and treatment needed. publications.ersnet.org

6. Airway-centered OP: OP changes clustered around small airways; may be seen with inhalational exposures or autoimmune disease. publications.ersnet.org

7. Nodular OP: Multiple nodules, sometimes cavitating; requires exclusion of infection and malignancy. publications.ersnet.org

Causes

1. Viral infections (post-viral): After an acute viral illness, lingering inflammation can “organize” into tissue plugs rather than resolve, leaving patchy opacities. www.elsevier.com

2. Bacterial pneumonia (post-infectious): Even when bacteria clear, the cleanup phase may misfire and form OP instead of normal recovery. www.elsevier.com

3. Fungal or atypical infections (triggering OP): In some patients, OP appears as a secondary response after these infections; cultures and stains help rule out active infection. www.elsevier.com

4. Connective-tissue diseases (e.g., rheumatoid arthritis, dermatomyositis, Sjögren’s): Systemic auto-inflammation can target the lung and present as OP. www.elsevier.com

5. Inflammatory bowel disease: Extra-intestinal lung inflammation may present as OP in rare cases. www.elsevier.com

6. Drug-induced OP – amiodarone: The antiarrhythmic amiodarone can injure lung tissue and trigger OP; stopping the drug is critical. www.elsevier.com

7. Drug-induced OP – nitrofurantoin: Long-term prophylaxis for UTIs can inflame lungs and lead to OP-pattern injury. www.elsevier.com

8. Drug-induced OP – methotrexate or other DMARDs: Immune-modifying drugs occasionally cause lung injury with OP changes. www.elsevier.com

9. Chemotherapy (e.g., bleomycin, cyclophosphamide): Some cancer drugs injure alveoli and provoke OP-type repair. www.elsevier.com

10. Immune checkpoint inhibitors: Potent anticancer immunotherapies can cause OP-pattern pneumonitis as an immune-related adverse event. www.elsevier.com

11. Radiation therapy to the chest (post-radiation OP): Inflammation can extend beyond the field of radiation and evolve into OP; imaging may show the reversed halo (atoll) sign. journalpulmonology.org

12. Environmental inhalational exposures: Organic dusts, molds, or fumes can irritate the small airways and promote organizing injury. publications.ersnet.org

13. Aspiration of gastric contents: Chemical injury from acid can start an organizing repair response in dependent lung regions. publications.ersnet.org

14. Post-transplant states: After hematopoietic stem-cell or solid-organ transplant, immune shifts and infections can precipitate OP. publications.ersnet.org

15. Post-COVID inflammatory lung disease: In some recovering patients, persistent opacities reflect organizing inflammation rather than active infection. publications.ersnet.org

16. Post-surgery or trauma to the lung: Local injury can heal via the OP pathway, creating focal or multifocal consolidations. publications.ersnet.org

17. Vasculitis or eosinophilic lung diseases (as overlaps): These can coexist and show OP areas; careful differential diagnosis is needed. publications.ersnet.org

18. Malignancy-related (paraneoplastic) inflammation: Rarely, tumor-related immune activity is associated with OP-pattern changes. publications.ersnet.org

19. Organizing response around pulmonary infarcts or emboli: Ischemic injury can organize in surrounding lung tissue. publications.ersnet.org

20. Idiopathic (cryptogenic) – no cause found: After excluding the above triggers, many patients are labeled COP; this is the most commonly reported category in specialty clinics. PubMed Central

Symptoms

1. Dry, persistent cough that does not improve with routine antibiotics. Wikipedia

2. Shortness of breath on exertion, sometimes at rest when more extensive. Wikipedia

3. Low-grade fever or feeling feverish due to ongoing lung inflammation. Wikipedia

4. Fatigue and tiredness, often out of proportion to activity level. Wikipedia

5. Unintentional weight loss over weeks because of chronic inflammation. Wikipedia

6. Malaise and flu-like feeling, especially early in the course. PubMed Central

7. Pleuritic chest pain (sharp pain with deep breaths) if the pleura is irritated. PubMed Central

8. Night sweats in some patients with active inflammation. PubMed Central

9. Wheezing or chest tightness when small airways are involved. PubMed Central

10. Breathlessness that “moves around” as opacities migrate on scans. publications.ersnet.org

11. Symptoms lasting weeks to a few months, not the 3–7 days typical of bronchitis. PubMed Central

12. Symptoms recur after feeling better—relapses are part of the natural history in a subset. MSD Manuals

13. Exercise intolerance and easy windedness on stairs or hills. PubMed Central

14. Hypoxemia (low oxygen) in more extensive disease; may cause headaches or confusion. PubMed Central

15. Rare hemoptysis (blood in sputum); prompts evaluation for other diagnoses too. PubMed Central

Diagnostic tests

A) Physical exam (bedside assessment)

1. Vital signs: Fever, faster breathing, or low oxygen saturation suggest active lung inflammation rather than simple bronchitis. PubMed Central

2. Pulse oximetry at rest: A clip on a finger estimates oxygen level; low numbers point to significant involvement. PubMed Central

3. Chest auscultation: Fine crackles over affected areas are common; wheeze may appear with airway-centered disease. PubMed Central

4. Work of breathing: Using neck/shoulder muscles or rapid shallow breaths signals respiratory strain. PubMed Central

5. Signs of systemic disease: Joint swelling, muscle weakness, rashes, dry eyes/mouth can hint at autoimmune causes that lead to secondary OP. www.elsevier.com

B) “Manual” tests (simple functional checks you can do in clinic)

6. Six-Minute Walk Test (6MWT): Walking on a flat surface while monitoring oxygen helps uncover exertional desaturation typical of interstitial processes like OP. PubMed Central

7. Exertional pulse-ox check (stairs or treadmill): Brief exertion can reveal oxygen drops that aren’t obvious at rest. PubMed Central

8. Peak cough/flow observation: Not a formal lab test, but a clinician-observed weak or hacking dry cough supports a parenchymal process rather than pure asthma. PubMed Central

9. Chest expansion measurement: Reduced excursion can reflect painful breaths or stiffness from widespread inflammation. PubMed Central

10. Borg dyspnea scale during walk: A simple rating of breathlessness that tracks response to therapy over time. PubMed Central

C) Laboratory & pathological testing

11. CBC, CRP, and ESR: Often show mild leukocytosis and elevated inflammatory markers; they support inflammation but are not specific. PubMed Central

12. Procalcitonin: May be low/normal in nonbacterial inflammation and helps argue against ongoing bacterial pneumonia when cultures are negative. PubMed Central

13. Microbiology (sputum/BAL cultures, viral PCR): Essential to exclude active infection before labeling OP, because the imaging can look like pneumonia. PubMed Central

14. Autoimmune serology (ANA, RF/anti-CCP, myositis panel): Screens for connective-tissue diseases that commonly cause secondary OP. www.elsevier.com

15. Bronchoscopy with bronchoalveolar lavage (BAL): Useful to rule out infection and sample inflammation; OP often shows a lymphocyte-predominant pattern, but findings are not specific and must be interpreted with the whole picture. publications.ersnet.org+1

16. Transbronchial or surgical lung biopsy: Pathology shows intraluminal plugs of granulation tissue (Masson bodies) in alveoli and small bronchioles with preservation of overall architecture—the histologic hallmark that confirms OP in the right context. NCBI

D) Electrodiagnostic/physiologic testing

17. Spirometry and lung volumes: Often reveal a restrictive pattern and reduced total lung capacity; may be near normal in focal disease. Diffusing capacity (DLCO) is commonly reduced. PubMed Central

18. Arterial blood gas (ABG): Measures oxygen and carbon dioxide directly; helps assess severity and need for oxygen therapy. PubMed Central

19. Cardiopulmonary exercise testing (with ECG monitoring): Distinguishes cardiac from pulmonary limitation and quantifies gas-exchange impairment in complex cases. PubMed Central

20. Electrocardiogram (ECG): Not a lung test, but rules out cardiac causes of breathlessness when the picture is unclear, especially in older patients. PubMed Central

E) Imaging (cornerstones of diagnosis)

• Chest X-ray: Shows patchy, often peripheral consolidations that may “migrate” from one area to another between films. This mobility is a useful clue to OP. publications.ersnet.org

• High-resolution CT (HRCT): The key test. Typical findings include peripheral or peribronchial consolidations, ground-glass opacities, small nodules, and sometimes the reversed halo (atoll) sign—a central ground-glass area surrounded by a ring of denser consolidation. The atoll sign is suggestive of OP but not fully specific. radiopaedia.org+2PubMed Central+2

• PET-CT: Lesions can be FDG-avid, potentially mimicking cancer; tissue confirmation is often needed for mass-like OP. publications.ersnet.org

• Follow-up CT: Demonstrates migration or resolution with treatment, supporting the diagnosis and tracking relapse. jtd.amegroups.org

Non-pharmacological treatments (therapies & other supports)

1) Pulmonary rehabilitation (PR).
A supervised program of breathing training, education, and exercise that reduces breathlessness and improves quality of life across chronic lung diseases; principles translate to ILD/OP. Typical plan: 2–3 sessions/week for 6–8 weeks plus home exercises. Expect gains in walk distance, symptoms, and confidence with activity; effects are strongest in COPD but extend to ILD with adapted intensity and oxygen support. Include pacing, energy-conservation, stair strategy, and airway clearance education as needed. PubMed Central+1

2) Home and ambulatory oxygen (for those who desaturate).
If oxygen levels are low at rest or drop with walking, supplemental oxygen can relieve hypoxemia, improve exercise tolerance, and protect organs. Guidelines give strong support for oxygen in ILD with severe resting hypoxemia and conditional support for ambulatory oxygen when saturation falls on exertion. Education on flow settings, safety (no smoking/open flames), and portable systems matters. atsjournals.org+1

3) Breathing retraining (diaphragmatic/pursed-lip).
Simple techniques slow the breathing rate, improve ventilation, and reduce dynamic air trapping during exertion. They are commonly packaged within pulmonary rehab and can help ease anxiety related to breathlessness. PubMed Central

4) Airway clearance when sputum is present.
Though OP often causes a dry cough, some patients have mucus; active cycle breathing, huff cough, and oscillatory PEP devices can help move secretions and reduce cough burden during respiratory infections or overlap disease. PubMed Central

5) Early, gentle physical activity & graded exercise.
Regular, paced walking or cycling preserves muscle, lowers fatigue, and supports mental health. Start low, go slow, use the talk test or pulse oximeter, and rest before breathlessness peaks. Exercise prescriptions are core within PR. PubMed Central

6) Vaccination (flu, pneumococcal, COVID-19, others as indicated).
Vaccines reduce the risk of infections that can trigger OP flares or complicate steroid therapy. Current ACIP/CDC adult schedules recommend annual influenza vaccination and expanded pneumococcal coverage (PCV15/20/21 strategies) for older adults and those with chronic lung disease. CDC+2CDC+2

7) Smoking cessation & avoidance of second-hand smoke.
Stopping smoking improves overall lung defense, reduces infection risk, and enhances exercise gains from PR; avoidance of smoke/irritants prevents symptom flares. PubMed Central

8) Environmental control (occupational/home triggers).
If OP is secondary to inhaled exposures (e.g., dusts, fumes, molds), identify and remove them. Worksite safety measures and home damp-mold remediation help prevent ongoing injury that keeps “organizing” active. PubMed

9) Nutrition support (balanced, anti-inflammatory pattern).
People with lung disease often lose weight/muscle or gain weight on steroids. Emphasize protein adequacy, fruits/vegetables, whole grains, and healthy fats; coordinate with a dietitian to counter steroid-related side effects (salt retention, glucose swings). Observational data link omega-3 intake with slower lung function decline, though trials are mixed. PubMed

10) Sleep optimization & reflux control.
Good sleep supports immunity and healing. Treat reflux (which can worsen cough) with lifestyle steps—early evening meals, head-of-bed elevation, trigger avoidance—and medical therapy if needed. These are standard supportive measures in chronic respiratory care. PubMed Central

11) Energy conservation & pacing strategies.
Break tasks into smaller steps, sit for chores, pre-plan rests, and use rollators or carts to reduce breathlessness spikes; taught routinely in PR programs. PubMed Central

12) Psychological support (CBT/mindfulness).
Anxiety can amplify breathlessness; brief CBT, relaxation, and mindfulness training reduce symptom distress and improve coping in chronic lung disease populations. publications.ersnet.org

13) Infection-prevention hygiene.
Hand hygiene, masking during surges, prompt evaluation of fevers, and avoiding sick contacts are prudent, especially when using steroids or other immunosuppressants. CDC

14) Fall-risk & bone health measures during steroids.
Weight-bearing activity, calcium/vitamin D adequacy, and home fall-proofing help counter steroid-related osteoporosis and myopathy. Labeling for systemic steroids highlights infection and bone risks; clinicians often add bone-protective strategies. FDA Access Data+1

15) Heat-and-smog day planning.
On poor air-quality days, stay indoors with filtered air, shift exercise to better times, and pre-position rescue strategies; omega-3 exposure data suggest air-pollution effects on lungs may be modified by diet, but primary protection is exposure reduction. pubs.acs.org

16) Address medication adherence & inhaler technique (if any).
If inhaled bronchodilators or steroids are used for overlap diseases, correct technique and adherence improve symptom control; PR programs routinely review technique. PubMed Central

17) Return-to-work/activity counseling.
Graduated return plans matched to oxygen and exertional tolerance reduce setbacks after the acute OP phase. PubMed Central

18) Advance care planning for rare progressive cases.
Most OP recovers well, but a minority develop fibrosing ILD. Early discussion of goals and preferences ensures care matches values if disease progresses. Frontiers

19) Caregiver education.
Teach spotting early flare signs (rising cough, fevers, desaturation), oxygen safety, and when to call for help; this improves outcomes in chronic lung disease. American Thoracic Society

20) Multidisciplinary ILD clinic follow-up.
Coordinated care with pulmonology, radiology, pathology, rehab, and sometimes rheumatology improves diagnostic confidence and tailored therapy for OP. thoracrespract.org

---

Drug treatments

Important: No drug is FDA-approved specifically for OP/COP. Corticosteroids are first-line in guidelines and reviews, and other immunomodulators are used off-label for relapsing/refractory disease. FDA labeling is cited for safety/pharmacology, not for an OP indication. Decisions must be individualized by a specialist. Frontiers+1

1) Prednisone (oral corticosteroid).
Class: Systemic glucocorticoid. Typical dose/time: Many clinicians start ~0.5–1 mg/kg/day, tapering over months guided by symptoms, imaging, and lung tests. Purpose: Calm the organizing inflammatory process so plugs resolve and gas exchange improves. Mechanism: Gene-level anti-inflammatory effects—reduced cytokines, immune cell trafficking, and fibroblast activity. Side effects: Infection risk, hyperglycemia, mood changes, insomnia, fluid retention, hypertension, osteoporosis, cataracts; taper to avoid adrenal suppression. FDA label reinforces infection and taper cautions. Frontiers+1

2) Methylprednisolone (IV “Solu-Medrol”).
Class: IV glucocorticoid. Use: For severe presentations or when oral therapy is not possible; sometimes given as short IV pulses before oral taper. Mechanism/purpose: Same as prednisone; faster onset IV. Key safety: Hyperglycemia, infection risk, psychiatric effects; benzyl alcohol cautions in neonates (not OP-specific). FDA Access Data

3) Prednisolone (liquid/alternative oral steroid).
Class: Systemic glucocorticoid. Use: Alternative to prednisone when solution is preferred. Safety: Label warns not to stop abruptly and highlights infection risks similar to other steroids. FDA Access Data

4) Azithromycin (macrolide) as steroid-sparing aid in mild/refractory COP (off-label).
Class: Macrolide antibiotic with immunomodulatory actions. Typical use: Low-dose courses (e.g., 250–500 mg 3x/week) have been reported in mild COP or as adjuncts to reduce steroid exposure; clinician-directed only. Mechanism: Down-regulates neutrophil chemotaxis and cytokines beyond antibacterial effect. Cautions: QT prolongation, drug interactions; antibiotic stewardship applies. FDA label covers approved infections, not OP. PubMed Central+2journalpulmonology.org+2

5) Clarithromycin (alternative macrolide adjunct; off-label).
Similar rationale to azithromycin in small series/case reports; consider interaction profile and QT risk. FDA label details dosing and contraindications (e.g., certain antiarrhythmics). publications.ersnet.org+1

6) Mycophenolate mofetil (steroid-sparing in relapsing OP; off-label).
Class: Antimetabolite immunosuppressant used widely in ILD with autoimmune features. Mechanism: Inhibits inosine monophosphate dehydrogenase → fewer lymphocytes. Monitoring: CBC, liver tests, pregnancy prevention. Label provides safety framework. FDA Access Data

7) Azathioprine (steroid-sparing; off-label).
Class: Purine antimetabolite. Use: Selected steroid-intolerant or relapsing OP when autoimmune overlap suspected. Risks: Myelosuppression, hepatotoxicity, malignancy; TPMT/NUDT15 status may guide safety. Label carries boxed warnings. FDA Access Data

8) Cyclophosphamide (rescue for severe steroid-refractory OP; off-label).
Class: Alkylating immunosuppressant. Use: Rare, severe cases; short courses with close monitoring. Risks: Cytopenias, infections, hemorrhagic cystitis—ensure hydration and uroprotection when appropriate. Labels outline dosing ranges and urotoxicity warnings. FDA Access Data+2FDA Access Data+2

9) Rituximab (B-cell depletion; off-label).
Class: Anti-CD20 monoclonal antibody. Use: Selected autoimmune-linked OP unresponsive to steroids/other agents; evidence from case reports/series. Risks: Infusion reactions, HBV reactivation, PML—screen and monitor. Labels provide detailed warnings. FDA Access Data+2FDA Access Data+2

10) Nintedanib (antifibrotic; off-label in progressive fibrosing ILD phenotype).
Class: Tyrosine kinase inhibitor approved for IPF, SSc-ILD, and progressive fibrosing ILDs. Use in OP: Not standard; may be considered if the disease evolves into a chronic fibrosing ILD with progression despite immunosuppression. Key effects/risks: Slows FVC decline; diarrhea, liver enzyme elevations. Regulatory docs outline indications and data. FDA Access Data+1

11) Medrol (methylprednisolone tablets).
An oral steroid alternative when tapering; same benefits/risks as prednisone with dose equivalence considerations. Label details infection and bone risks. FDA Access Data

12) Rayos (delayed-release prednisone).
Use: Night-time dosing can align peak steroid levels with early-morning cytokine surges to potentially reduce morning symptoms; chosen case-by-case during steroid tapers. Label reiterates taper/infection cautions. FDA Access Data

13) High-dose IV methylprednisolone “pulse.”
Use: Occasionally used (e.g., 500–1000 mg/day for 3 days) in fulminant OP patterns before oral taper; practice is extrapolated from ILD rescue strategies; monitor glucose and infection closely. Evidence base is observational. Label for IV product informs safety. FDA Access Data

14) Trimethoprim-sulfamethoxazole (PJP prophylaxis during high-dose immunosuppression; off-label in OP).
Purpose: Prevent Pneumocystis jirovecii pneumonia when steroid doses are high/combined with other agents. Mechanism: Folate pathway inhibition in microbes. Note: This is prophylaxis, not OP treatment. (General practice reflected across ILD immunosuppression literature.) Frontiers

15) Proton-pump inhibitor (for steroid-related GI protection/GERD).
Helps manage reflux that aggravates cough and protects GI mucosa during steroid courses when indicated; individualize duration and risks (e.g., infections). Frontiers

16) Calcium + Vitamin D (bone protection during steroids).
Supports bone health; consider DXA and bisphosphonates per fracture risk. Steroid labels highlight osteoporosis risk; supplementation is part of standard prevention bundles. FDA Access Data

17) Bisphosphonate (e.g., alendronate) when fracture risk is high.
Not an OP drug but reduces glucocorticoid-induced bone loss; chosen per guidelines when on prolonged systemic steroids. FDA Access Data

18) Insulin or antihyperglycemics during steroid therapy (when needed).
Short-term glucose control may be required; steroid labels note hyperglycemia risk—monitor and treat per diabetes standards. FDA Access Data

19) PJP prophylaxis alternatives (atovaquone/dapsone) if TMP-SMX is not tolerated.
Selected based on allergies and blood counts; again, prophylaxis decision depends on steroid dose/combinations. Frontiers

20) Vaccines administered appropriately with timing around immunosuppression.
Coordinate inactivated vaccines (influenza, pneumococcal, COVID-19) before or during therapy; avoid live vaccines on significant immunosuppression. Follow ACIP notes. CDC

---

Dietary molecular supplements

Note: No supplement cures OP. Some support overall lung/immune health; evidence ranges from observational to mixed RCTs. Discuss interactions with your clinician.

1) Omega-3 fatty acids (EPA/DHA).
Dose often used: 1–2 g/day combined EPA/DHA. Function/mechanism: Anti-inflammatory lipid mediators (resolvins/protectins) may modulate lung inflammation; observational data link higher omega-3 levels to slower lung function decline; RCTs in acute lung injury are mixed. PubMed+1

2) Vitamin D (for bone/immune health).
Dose: Individualized to achieve sufficiency (commonly 800–2000 IU/day; test-guided). Function/mechanism: Modulates innate/adaptive immunity and supports bone while on steroids; recent meta-analyses show little/no effect on preventing acute respiratory infections overall—benefit uncertain for lungs but bone benefit is clear. PubMed Central

3) N-Acetylcysteine (NAC).
Dose used in studies: 600 mg 2–3 times daily (varies). Function/mechanism: Antioxidant and mucolytic; large IPF trials showed no preservation of FVC with oral NAC, and some combinations were harmful; consider only for mucus management, not disease modification. PubMed Central+1

4) Magnesium (deficiency replacement).
Supports muscle function, including respiratory muscles; correct documented deficiency to help cramps or fatigue; routine high-dose use lacks lung-specific proof. PubMed Central

5) Probiotics (general immune modulation).
May reduce some upper respiratory infections in meta-analyses, but no OP-specific data; choose evidence-based strains and avoid in severe immunosuppression without medical advice. CDC

6) Curcumin (turmeric extract).
Anti-inflammatory signaling effects in preclinical work; human respiratory evidence is limited and interactions exist (anticoagulants). Use cautiously, if at all. PubMed Central

7) Quercetin (polyphenol).
Antioxidant actions; clinical benefits in lung disease remain uncertain; avoid high doses around chemotherapy due to interactions. PubMed Central

8) Zinc (if deficient).
Important for immune function; correct deficiency only—excess causes copper deficiency and anemia; does not treat OP. CDC

9) Selenium (if deficient).
Part of antioxidant enzymes; correct deficiency cautiously; routine supplementation lacks OP evidence. PubMed Central

10) Protein supplements (whey/plant) when appetite is low.
Help maintain lean mass during illness and steroid therapy; target 1.0–1.2 g/kg/day total protein unless otherwise directed. PubMed Central

---

Immunity-booster / regenerative / stem-cell” drugs

Plain truth: There are no approved “immunity booster” or stem-cell drugs for OP. Mesenchymal stem-cell therapies are investigational, with uncertain benefits and risks. What is used are immunosuppressive medicines to quiet the abnormal organizing inflammation. Below are six items to clarify the landscape and support safe decisions:

1) Evidence-based immunosuppression (steroids).
Systemic corticosteroids remain the cornerstone for COP, with generally good response and relapse control when tapered carefully. Frontiers

2) Steroid-sparing agents (mycophenolate, azathioprine).
Used off-label when patients cannot tolerate steroids or relapse; selected for autoimmune overlap patterns and monitored closely per FDA-label safety. FDA Access Data+1

3) Rescue cytotoxic therapy (cyclophosphamide) in severe refractory OP.
Short courses under specialist care only; risks and monitoring are substantial. FDA Access Data

4) B-cell depletion (rituximab) for autoimmune-linked refractory disease.
Considered case-by-case; strict screening for HBV and infusion safety is mandatory per label. FDA Access Data

5) Antifibrotics (nintedanib) when OP behaves like progressive fibrosing ILD.
Not OP-specific, but may slow decline in a PF-ILD phenotype after specialist assessment. FDA Access Data

6) Clinical trials—not stem-cell clinics.
If disease progresses despite standard care, discuss referral to ILD centers and regulated trials; avoid unregulated “stem-cell” offerings. publications.ersnet.org

---

Surgeries (procedures) & why they’re done

1) Video-assisted thoracoscopic surgery (VATS) lung biopsy.
Purpose: obtain adequate tissue when diagnosis is uncertain after CT/BAL/bronchoscopy. Benefits: highest diagnostic yield; Risks: postoperative pain, air leak, rare mortality (~3% within 90 days in ILD series). jtd.amegroups.org+1

2) Transbronchial lung biopsy or cryobiopsy (via bronchoscopy).
Less invasive than VATS; may confirm OP in selected patterns, though samples can be small. Cryobiopsy improves yield with careful technique. thoracrespract.org

3) Bronchoalveolar lavage (BAL).
Washes cells from the lung to exclude infections/allergic or eosinophilic processes and support an OP diagnosis alongside imaging. thoracrespract.org

4) CT-guided percutaneous needle biopsy (PTNB).
Alternative when a peripheral lesion is accessible; used selectively by ILD teams. thoracrespract.org

5) Lung transplantation (very rare for OP).
For exceptional cases where OP has evolved into end-stage fibrosing ILD despite maximal therapy; ISHLT criteria guide referral/selection. jhltonline.org+1

---

Preventions

1. Keep vaccines current (influenza annually; pneumococcal per ACIP; COVID-19). CDC+1

2. Avoid smoking and second-hand smoke; eliminate occupational/home irritants. PubMed Central

3. Hand hygiene and masking during outbreaks or when immunosuppressed. CDC

4. Medication review: promptly report new cough after starting drugs known to trigger OP (e.g., amiodarone, some chemo/radiation). PubMed

5. Treat reflux and post-nasal drip to reduce cough irritation. PubMed Central

6. Plan exercise and rest (pacing) to prevent deconditioning. PubMed Central

7. Oxygen safety and adherence, if prescribed. atsjournals.org

8. Bone protection during steroid courses (calcium/vitamin D, weight-bearing activity; consider bisphosphonate if high risk). FDA Access Data

9. Air-quality awareness: limit outdoor exertion on heavy pollution/smog days. pubs.acs.org

10. Regular follow-up with an ILD team; act early on new fevers, chest pain, or oxygen dips. thoracrespract.org

---

When to see a doctor (now vs soon)

• Now/urgent: Worsening breathlessness at rest, oxygen saturation falling (<90% if you have a home oximeter), high fever with chills, chest pain, coughing up blood, confusion, or blue lips/fingertips—especially if you’re on steroids or other immunosuppressants (higher infection risk). FDA Access Data

• Soon (within days): New or persistent cough >2–4 weeks, exertional breathlessness limiting daily tasks, unexplained weight loss or fatigue, or relapse of symptoms during/after steroid taper. Frontiers

---

What to eat & what to avoid

• Eat: Protein at each meal (fish, eggs, legumes, lean meats) to maintain muscles—especially during steroids and rehab. PubMed Central

• Eat: Fruits, vegetables, whole grains, nuts, and olive-oil-type fats for overall anti-inflammatory balance. PubMed

• Eat: Calcium- and vitamin-D-rich foods (dairy or fortified alternatives) for bone health on steroids. FDA Access Data

• Eat: Adequate fluids unless restricted—helps with mucus and overall well-being. PubMed Central

• Avoid/limit: Ultra-processed foods high in salt/sugar (worsen steroid fluid retention and glucose). FDA Access Data

• Avoid: Smoking and indoor pollutants; keep the kitchen well-ventilated when cooking. PubMed Central

• Avoid: Large late-night meals, mint/chocolate/alcohol if reflux worsens cough. PubMed Central

• Avoid: Unverified “immune boosters” and high-dose supplements without clinician review (interactions, side effects). FDA Access Data

• Consider: Omega-3-rich foods (fatty fish, walnuts) as part of meals; supplement evidence is mixed. PubMed

• Consider: Dietitian guidance if weight is falling or rising quickly on steroids. PubMed Central

---

Frequently Asked Questions

1) Is BOOP the same as COP?
BOOP and OP refer to the same pattern; COP means OP with no identifiable cause. Many experts now prefer “OP/COP” instead of BOOP. atsjournals.org

2) What causes OP?
It’s a nonspecific repair response after lung injury—triggers include infections, drugs, connective-tissue disease, inhalation exposures, radiation, or none found (COP). publications.ersnet.org+1

3) How is OP diagnosed?
By symptoms, characteristic CT patterns, exclusion of infection/other ILDs, and sometimes lung biopsy to confirm. thoracrespract.org

4) Do most people get better?
Yes—most improve significantly with steroids, though some relapse during the taper; a minority progress to fibrosis. Frontiers

5) How long will I need steroids?
Commonly months, with a gradual taper guided by symptoms, lung tests, and imaging; exact duration varies. Frontiers

6) Are macrolides real treatments?
In mild cases or as adjuncts, low-dose macrolides have immunomodulatory effects in small studies; use is off-label and clinician-directed. PubMed Central

7) What if I can’t tolerate steroids?
Specialists may use steroid-sparing immunosuppressants (e.g., mycophenolate, azathioprine) off-label with careful monitoring. FDA Access Data+1

8) Can OP turn into pulmonary fibrosis?
Rarely, OP behaves like a progressive fibrosing ILD; antifibrotics (nintedanib) may be considered off-label in that phenotype. FDA Access Data

9) Do inhalers help?
OP is mainly a parenchymal process, so inhalers are not primary therapy; they may help if asthma/COPD overlap exists. Frontiers

10) Will oxygen be permanent?
Not necessarily. Some need oxygen only during the worst phase or with exertion; reassess after treatment and rehab. atsjournals.org

11) Is lung biopsy always required?
No. With classic clinical/CT features and exclusion of infection, experts sometimes treat without biopsy; biopsy is used when the diagnosis is uncertain. thoracrespract.org

12) Are supplements helpful?
No supplement treats OP. Focus on nutrition, bone protection during steroids, and only correct clear deficiencies. PubMed Central

13) Can OP recur?
Yes, relapses can occur, especially with rapid steroid tapers; regular follow-up catches flares early. Frontiers

14) Is transplant in my future?
Very unlikely. Only rare, progressive fibrotic cases consider transplant using ISHLT criteria. jhltonline.org

15) What’s the outlook?
Overall favorable with appropriate therapy and follow-up; most regain function and quality of life. Frontiers

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: November 02, 2025.